Status: Recruiting
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Participants needed: 10
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Marina KremyanskayaUpdated: Apr 6, 2025Locations: 1
Eligibility criteria
Subjects must be ≥18 years of age at the time of signing the informed consent fo... [+13]
Other invasive malignancy in the past 3 years except non-melanoma skin cancer, l... [+11]